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Abstract  
RNA editing is a post-transcriptional process that alters the nucleotide sequence of RNA 
transcripts to generate transcriptome diversity. Among the various types of RNA editing, 
adenosine-to-inosine (A-to-I) RNA editing is the most frequent type of RNA editing in 
mammals. Adenosine deaminases acting on RNA (ADAR) enzymes, ADAR1 and ADAR2, 
convert adenosines in double-stranded RNA structures into inosines by hydrolytic 
deamination. Inosine forms a base pair with cytidine as if it were guanosine; therefore, the 
conversion may affect the amino acid sequence, splicing, microRNA targeting, and miRNA 
maturation. It became apparent that disrupted RNA editing or abnormal ADAR expression is 
associated with several diseases including cancer, neurological disorders, metabolic diseases, 
viral infections, and autoimmune disorders. The biological significance of RNA editing in 
pharmacokinetics/ pharmacodynamics (PK/PD)-related genes is starting to be demonstrated. 
The authors conducted pioneering studies to reveal that RNA editing modulates drug 
metabolism potencies in the human liver, as well as the response of cancer cells to 
chemotherapy agents. Awareness of the importance of RNA editing in drug therapy is 
growing. This review summarizes the current knowledge on the RNA editing that affects the 
expression and function of drug response-related genes. Continuing studies on the RNA 
editing that regulates pharmacokinetics/pharmacodynamics would provide new beneficial 
information for personalized medicine. 
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ABC, ATP-binding cassette transporter; ADAR, adenosine deaminase acting on RNA; ADH, 
alcohol dehydrogenase; AhR, aryl hydrocarbon receptor; AKR, aldo-keto reductase; ALS, 
amyotrophic lateral sclerosis; AZIN1, antizyme inhibitor 1; AMPA, -amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid; A-to-I, adenosine-to-inosine; BCRP, breast cancer 
resistance protein; CAR, constitutive androstane receptor; CES, carboxylesterase; COMT, 
catechol O-methyltransferase; CYP, cytochrome P450; DHFR, dihydrofolate reductase; 
dsRNA, double-stranded RNA; ER, estrogen receptor; FMO, flavin-containing 
monooxygenase; FXR, farnesoid X receptor; GluR2, glutamate receptor 2; GR, 
glucocorticoid receptor; HCC, hepatocellular carcinoma; HNF, human hepatocyte nuclear 
factor; LXR, liver X receptors; miRNA, microRNA; MRP, multidrug resistance-associated 
protein; NR, nuclear receptor; OAT, organic anion transporter; OATP, organic anion 
transporting polypeptide; OCT, organic cation transporter; OCTN, organic cation/carnitine 
transporter; PCA, prostate cancer antigen; PD, pharmacodynamics; PEPT, peptide transporter; 
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P-gp, P-glycoprotein; PK, pharmacokinetics; PPAR, peroxisome proliferator-activated 
receptor; Pre-miRNA, precursor microRNA, Pri-miRNA, primary microRNA; PXR, 
pregnane X receptor; SLC, solute carrier family; SLCO, solute carrier organic anion 
transporter; SULT, sulfotransferase; T2DM, Type 2 diabetes mellitus; TPMT, thiopurine S-
methyltransferase; UGT, UDP-glucuronosyltransferase; URAT, urate transporter; UTR, 
untranslated region; VDR, vitamin D receptor 
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1. Introduction 
Gene regulation occurs at every step in the central dogma. In addition to regulatory 
mechanisms that act on DNA and proteins, eukaryotic RNA transcripts are subjected to 
various processing, such as alternative splicing, nucleotide modification and localization. 
Among such regulatory mechanisms, RNA editing refers to sequence alterations, including 
insertion, deletion or nucleotide conversion, that offer diversity in the transcriptome. 
Adenosine-to-inosine (A-to-I) RNA editing is a predominant form of RNA editing in 
mammals (Fig. 1) (Nishikura, 2010). In 1987, an enzymatic activity that causes the unwinding 
of double-stranded RNA (dsRNA) was discovered in Xenopus laevis oocytes and embryos 
(Bass & Weintraub, 1987). Later, this reaction was found to be the hydrolytic deamination of 
adenosine to form inosine, i.e., A-to-I RNA editing, which is catalyzed by adenosine 
deaminase acting on RNA (ADAR) enzymes (Bass & Weintraub, 1988; Wagner et al., 1989). 
At that time, a limited number of RNA editing sites were discovered in the coding region of 
mRNA by comparing the sequences of genomic DNA and cDNA using Sanger sequencing 
(Sommer et al., 1991). Within the past 10 years, the progress of next-generation sequencing 
technologies has enabled the high-throughput identification of 4.5 million A-to-I RNA editing 
sites, not only in the coding region but also in the non-coding region (Picardi et al., 2017). 
Since the base-paring property of inosine is similar to that of guanosine, the conversion of 
nucleotides potentially affects gene function and expression, depending on the region where 
the editing event occurs. For genes associated with pharmacokinetics (PK) and 
pharmacodynamics (PD), the roles of RNA editing have just started being studied. The 
purpose of this review is to outline recent findings on the role of RNA editing of PK/PD-
related genes and its potential pharmacotherapeutic implications. 
 
2. ADAR enzymes 
 ADAR enzymes convert the adenosines in dsRNA structures into inosines by hydrolytic 
deamination at the C6 position (Kim et al., 1994; Gerber et al., 1997). A highly conserved 
deaminase domain in the C-terminal region and dsRNA-binding domains in the N-terminal 
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region of ADARs catalyze this reaction (Nishikura, 2016). In the ADAR family in 
vertebrates, there are three members, ADAR1, ADAR2, and ADAR3 (also called ADAR, 
ADARB1, and ADARB2, respectively) (Bass et al., 1997). The ADAR1 gene encodes two 
isoforms, ADAR1 p110 (110 kDa protein) and ADAR1 p150 (150 kDa protein), using 
different transcription initiation sites and start codons. The former is constitutively expressed 
and is localized in the nucleus whereas the expression of the latter is induced by interferon 
and exists in both the nucleus and the cytoplasm (Patterson and Samuel, 1995; Desterro et al., 
2003). ADAR2, which is also a ubiquitous form, is highly expressed in the brain and is 
localized in nucleus (Melcher et al, 1996b). The expression of ADAR3 is limited to the brain 
(Melcher et al., 1996b; Chen et al., 2000). ADAR1 (Kim et al., 1994) and ADAR2 (Melcher 
et al., 1996a) have A-to-I RNA editing ability whereas ADAR3 does not show editing activity 
(Melcher et al., 1996b; Herbert et al., 1997; Chen et al., 2000). For ADAR1 and ADAR2, 
homodimerization is required to exert their editing activities (Cho et al., 2003; Poulsen et al., 
2006; Valente & Nishikura, 2007). Cho et al. (2003) have reported that ADAR3 is unable to 
homodimerize, which may account for its lack of editing activity. Although there is no strict 
sequence specificity for A-to-I editing, the surrounding nucleotides have some influence on 
recognition by ADARs. ADAR1 has a 5’ neighbor preference (A = U > C > G), but no 
apparent 3’ neighbor preference (Riedmann et al., 2008). The 5’ neighbor preference of 
ADAR2 (A ≈ U > C = G) is similar to that of ADAR1 whereas ADAR2 has a 3’ neighbor 
preference (U = G > C = A) (Polson & Bass, 1994). Some nucleotides are edited by either 
ADAR1 or ADAR2, and the others can be edited by both enzymes (Lehmann & Bass, 2000; 
Hartner et al., 2004).  
Mice genetically lacking either ADAR1 or ADAR2 were generated. It has been reported 
that the ADAR1-null mouse dies with numerous tissue failures at the embryogenesis stages 
(E11.5-12.5) (Wang et al., 2004), and the ADAR2-null mouse dies with epileptic seizures at 
postnatal day 20 (Higuchi et al., 2000), suggesting that ADAR proteins are indispensable for 
life. 
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3. Functional significance of A-to-I RNA editing of coding genes and miRNAs  
Following the conversion of adenosine into inosine, the nucleotide is interpreted as a 
guanosine, leading to a series of functional consequences depending on the site of A-to-I 
editing (Fig. 2) (Zipeto et al., 2015). Editing in the coding region of pre-mRNA may change 
the genetic code, resulting in a change in the amino acid sequence. Editing in the intron may 
affect splicing by generating or deleting alternative splice sites. The editing events within the 
3’-untranslated region (3’-UTR) have the potential to create or destroy the binding site of 
microRNAs (miRNAs) (Borchert et al., 2009; Farajollahi & Maas, 2010; Deffit & Hundley, 
2016).  
 miRNAs are short (~22-nucleotide), endogenous non-coding RNAs that regulate gene 
expression at the post-transcriptional level via base pairing with the target mRNA, resulting in 
gene silencing by either translational repression or mRNA degradation (Bartel, 2004). 
Nucleotides 2-8 at the 5’-end of the miRNA, called the seed sequence, are critical and 
sometimes sufficient for repressing the target translation (Lewis et al., 2005). The biogenesis 
of miRNA is a multi-step process. miRNAs are transcribed in the nucleus by RNA 
polymerase II as long primary transcripts (pri-miRNAs) containing a stem-loop structure. The 
pri-miRNAs are subsequently cleaved into 70-100 nt precursors (pre-miRNAs) by the 
microprocessor complex, which is composed of the RNase III, Drosha and DiGeorge 
syndrome critical region 8 (DGCR8). After they are exported into the cytoplasm by exportin 
5, pre-miRNAs undergo secondary cleavage by Dicer and TAR RNA binding protein (TRBP), 
leading to mature miRNA duplexes, and then they are unwound into the guide strand form of 
mature miRNAs. The passenger strand, named miRNA*, is usually degraded, but it is 
sometimes functional. The stem-loop structures of pri-miRNAs and pre-miRNAs are 
favorable targets for ADARs (Luciano et al., 2004; Kawahara et al., 2007). The A-to-I change 
in a miRNA transcript can alter its processing by changing the ability of Drosha and Dicer to 
bind to pri-miRNA and pre-miRNA, thereby affecting miRNA expression. In other cases, A-
to-I editing of the miRNA seed sequence could change its target selection or binding 
efficiency, although editing frequency in this region is low (Vesely et al., 2012; Ekdahl et al., 
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2012; Alon et al., 2012). With the finding of miRNAs, RNA editing became recognized as a 
critically important regulator of gene expression.  
In addition to A-to-I sequence change in miRNAs or their targets, ADAR regulates miRNA 
processing via an editing-independent mechanism (Nishikura et al., 2013). It has been 
reported that ADAR1 forms a complex with DGCR8 which is mutually exclusive  with the 
DGCR8-Drosha complex, leading to suppression of processing of pri-miRNA to pre-miRNA 
(Nemlich et al., 2013; Chen et al., 2015). Ota et al. (2013) revealed that ADAR1 forms a 
heterodimer with Dicer to function like TRBP, a Dicer’s partner. ADAR1 promotes Dicer-
dependent pre-miRNA cleavage, resulting the increase of generation of miRNAs. Thus, 
ADAR has a potential to modulate global miRNA synthesis. 
 
4. Databases of RNA editing sites  
Recent advances in next-generation sequencing enabled us to identify global RNA editing 
sites. RNA editing sites have been compiled in databases such as DARNED 
(http://darned.ucc.ie/, Kiran & Baranov, 2010; Kiran et al., 2013), RADAR 
(http://rnaedit.com/, Ramaswami & Li, 2014), and REDIportal 
(http://srv00.recas.ba.infn.it/atlas/, Picardi et al., 2017). According to RADAR, almost all of 
the editing sites (99.83%) are located in non-coding regions, including introns and UTR in 
coding genes as well as non-coding RNA molecules (Ramaswami & Li, 2016). A limited 
number of genes are edited in the coding regions, and their effects on protein function have 
been demonstrated (Pinto et al. 2014). Despite the broad distribution of editing sites in the 
non-coding regions, their physiological and functional significances largely remain to be 
clarified. The databases can help us to search for editing sites that may have biological 
significance. 
 
5. Diseases associated with RNA editing 
Accumulating evidence has demonstrated that disrupted RNA editing or abnormal ADAR 
expression in humans is linked with several diseases, including cancer, neurological disorders, 
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metabolic diseases, viral infections, and autoimmune disorders (Table 1) (Slotkin and 
Nishikura, 2013). In this section, the studies on the RNA editing that is associated with a 
neurological disorder, cancers and a metabolic disease are summarized.  
 
5.1. Neurological disorder 
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that is 
characterized by the selective death of motor neurons. Although mutations of the superoxide 
dismutase gene have been found in 20% of familial ALS patients (Rosen et al., 1993), the 
majority of ALS cases are sporadic. Glutamate receptor 2 (GluR2), a subunit of the -amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, is the first example that was 
found to be subjected to A-to-I editing in mammals (Sommer et al., 1991). The editing occurs 
in the coding region and causes an amino acid substitution, Q607R. This site is completely 
edited in neurons throughout life, starting in, from the embryonic stage onwards. Kawahara et 
al. (2004) found that its editing levels in the motor neurons from patients with sporadic ALS 
were lower than those in healthy subjects. Motor neurons with less edited receptors had 
increased Ca2+, which resulted in cell death (Higuchi et al., 2000). Two research groups 
reported that the loss of editing of GluR2 is attributed to the decreased expression of ADAR2 
(Kawahara & Kwak, 2005; Aizawa et al., 2010), although the reason behind the down-
regulation of ADAR2 in ALS patients remains to be clarified. Hideyama et al (2010) have 
generated a conditional knockout mouse whose motor neurons lack ADAR2. These mice 
prematurely died with a neuronal defect (Hideyama et al., 2010), but the restoration of 
ADAR2 could rescue them, indicating that the editing of GluR2 is crucial for neuronal 
survival (Yamashita et al., 2013).  
Interestingly, a research group reported that antidepressants, such as paroxetine and 
imipramine, have the potency to enhance the editing of GluR2 at the Q/R site by up-
regulating ADAR2 expression (Sawada et al., 2009). Therefore, such drugs may have the 
potential to treat sporadic ALS. In addition, the Q607R substitution changes the affinity 
towards the Joro spider toxin (JSTX) isolated from Nephila clavata, which is one of the most 
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potent blockers of the AMPA receptor (Blaschke et al., 1993). Non-edited GluR2 has a higher 
affinity toward sJSTX than edited GluR2 (Iino et al., 1996; Savidge & Bristow, 1998). 
Therefore, inhibitors that are specific to the non-edited receptor may be an additional tool for 
ALS therapy.  
 
5.2. Cancers  
Tumor initiation and progression are the processes characterized by cellular changes in 
proliferation, differentiation and survival. Some genes and non-coding RNAs are involved in 
these processes as oncogenes or tumor suppressor genes. In addition, the effects of somatic 
mutations on cancer progression are well studied. RNA editing was also been found to be 
dysregulated in human cancers (Galeano et al., 2012). Interestingly, ADARs differentially 
function as oncogenes or tumor suppressive genes, depending on the cancer type, to cause 
hyper- or hypo-editing. Here, we summarize the studies demonstrating the role of A-to-I 
editing in cancer biology (Slotkin & Nishikura, 2013; Gallo & Locatelli, 2012).  
Hepatocellular carcinoma (HCC) is the third most common cause of cancer related deaths 
in the world. Recent studies demonstrated that the dysregulation of ADARs in tumors, which 
causes bankrupted editing, underlies tumor progression (Chen et al., 2013; Chan et al., 2014). 
Patients with up-regulated ADAR1 have an increased risk of liver cirrhosis, postoperative 
recurrence, and poor prognoses (Chan et al., 2014). In that study, the authors found that the 
mRNA of antizyme inhibitor 1 (AZIN1) is edited by ADAR1, leading to an S367G amino acid 
substitution (from AGC [serine] to GGC [glycine]). AZIN1 inhibits the antizyme-mediated 
degradation of cycle regulatory proteins, such as ornithine decarboxylase and cyclin D1 
(Coffino, 2001; Bercovich & Kahana, 2004; Newman et al, 2004; Kahana, 2009). The editing 
of AZIN1 mRNA resulted in the stabilization of AZIN1 protein and increased its binding to 
the antizymes to prevent the degradation of onco-proteins. Notably, the edited AZIN1 
conferred a tumorigenic phenotype to HCC cells that presented as higher proliferation and 
invasive ability, indicating that ADAR1 functions as an oncogene by enhancing the activity of 
AZIN1. A recent study revealed that Ba/F3 cells (murine dependent pro-B cell line) stably 
  11 
expressing edited AZIN1 shows a higher resistance to BMS536924, an IGF-1R inhibitor, than 
the cells expressing non-edited AZIN1 (Han et al., 2015). The authors found that the IC50 
value of chemotherapy agents, such as paclitaxel, irinotecan and topotecan, were correlated 
with the editing levels of AZIN1 in 740 cell lines from the Cancer Cell Line Encyclopedia 
(Barretina et al., 2012), suggesting that RNA editing could modulate the sensitivity of cancer 
cells to the drug. Another study revealed that ADAR2 expression is elevated in HCC tissues 
and that ADAR2-mediated RNA editing of pre-miR-214 resulted in a decrease in the mature 
miR-214 level, leading to increased expression of its target Rab15, a member of the RAS 
oncogene family.  
Melanoma is the most aggressive type of skin cancer. Shoshan et al. (2015) found that 
cyclic AMP-responsive element binding protein (CREB) negatively regulates ADAR1 
expression and that ADAR1 inhibits melanoma tumor growth and metastasis. It has been 
reported that RNA editing by ADAR1 suppresses the maturation of pri-miR-455. The 
decrease in ADAR1 expression results in the decreased editing of pri-miR-455, an increased 
mature miR-455-5p level, and decreased levels of its target, the tumor suppressor cytoplasmic 
polyadenylation element-binding protein 1 (CPEB1) in melanoma progression. 
Previous studies have revealed a decreased expression of ADAR2 in glioblastoma, which 
is the most aggressive type of brain cancer (Maas et al., 2001; Ishiuchi et al., 2002; Galeano et 
al., 2013). The restoration of ADAR2 in glioblastoma cells resulted in decreased proliferation 
and migration in vitro. As the biological mechanism, it has been reported that the phosphatase 
CDC14B, which regulates Skp2/p21/p27 and is involved in glioblastoma growth, is a target of 
ADAR2 (Galeano et al., 2013). Onco-miRNAs, pri-miR-21 and pri-miR-221/222 are edited 
by ADAR2, leading to a decrease in their mature miRNA levels (Tomaselli et al., 2015). The 
seed sequence of miR-376* is edited by ADAR2, but the editing is reduced in glioblastoma. 
Since non-edited miR-376* directly represses RAP2A (a member of RAS family) expression, 
the increase in the non-edited miR-376* level by a decreased editing level in glioblastoma 
facilitates the down-regulation of RAP2A (Choudhury et al., 2012). Interestingly, it has been 
revealed that hypo-editing of the coding region of GluR2 increases Ca2+ influx, leading to the 
  12 
promotion of glioblastoma growth (Ishiuchi et al., 2002). Thus, these studies indicate the 
essential role of ADAR2 in glioblastoma, with ADAR2 acting on multiple targets that 
contribute to cancer progression. 
The biological significance of RNA editing in cancer is not fully understood. Current 
knowledge of ADAR’s impact on human cancer development and progression may provide 
new ideas for developing drugs for cancer therapy. A study demonstrated that 2’-O-
methyl/locked nucleic acid mixmer antisense oligonucleotides against the target region of 
ADAR can be potent and selective inhibitors of RNA editing (Mizrahi et al., 2013). Site-
selective editing inhibitors could have therapeutic potential in cancers, which are 
characterized by hyper-editing at specific sites. 
 
5.3. Metabolic disease 
Type 2 diabetes mellitus (T2DM) is a metabolic disease characterized by the abnormal 
secretion and uptake of insulin. The glucose-stimulated secretion of insulin from pancreatic -
cells plays a pivotal role in the pathology of T2DM (Ashcroft & Rorsman, 2012). It has been 
revealed that ADAR2 expression in pancreatic -cells is up-regulated by glucose stimulation 
via the c-Jun amino-terminal kinase-1 pathway (Gan et al., 2006; Yang et al., 2012). Another 
study demonstrated that the knockdown of ADAR2 impairs the secretion of insulin via 
glucose stimulation, suggesting that ADAR2 is required for insulin secretion by the pancreatic 
-cells (Yang et al., 2010). Although the responsible target(s) of ADAR2 for insulin secretion 
has not been uncovered, ADAR2-knockdowned -cells exhibited a lower expression of two 
key molecules, Munc18-1 and synaptotamin-7, that are involved in vesicle exocytosis (Yang 
et al., 2010). Further studies are required to disclose the mechanism in which ADAR2 is 
associated with the glucose-stimulated insulin secretion in pancreatic -cells. 
 
6. RNA editing of human AhR, which modulates PK 
As mentioned above, the roles of RNA editing in human diseases is becoming clear. 
However, the significance of RNA editing of the mRNAs that regulate drug responses is 
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largely unknown. Recently, we found that there is a large inter-individual difference (220-
fold) in ADAR1 protein expression (whereas ADAR2 was not detected) in human livers 
(Nakano et al., 2016), which is the principal tissue of drug metabolism, indicating the 
possibility that interindividual differences in ADAR expression and RNA editing levels may 
affect the expression or function of drug metabolism-related genes. 
In RADAR, many PK-related genes, including drug-metabolism enzymes, drug 
transporters and transcriptional factors, are registered as mRNAs that are subjected to RNA 
editing (Table 2). Almost all of the RNA editing sites are located in non-coding regions, such 
as introns and 3’-UTR, suggesting a possibility that the RNA editing events may affect the 
splicing or expression of the concerned genes. However, the biological significance of their 
RNA editing is not fully understood. Recently, we demonstrated the first evidence of the 
impact of RNA editing on the expression of drug-metabolism enzymes, which is described as 
follows.  
AhR is a ligand-activated transcription factor that regulates the expression of xenobiotic-
metabolizing enzymes, including CYP1A1, CYP1A2, CYP1B1, UDP-
glucuronosyltransferase, glutathione S-transferase (Ramadoss et al., 2005). We found that 
there are 38 edited sites in the 3’-UTR of AhR mRNA in the human liver. ADAR1 is 
responsible for their editing, and ADAR1-mediated RNA editing negatively regulates AhR 
expression in human liver cells (Nakano et al., 2016) (Fig. 3). Interestingly, the down-
regulation of the AhR attenuated 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated induction of 
CYP1A1, a downstream gene of AhR, suggests that RNA editing affects the expression of 
P450s. For the underlying mechanism of the negative regulation of AhR, we found that RNA 
editing creates the binding site of miR-378 in the 3’-UTR of AhR. In the human liver 
samples, a significant inverse association was observed between the miR-378 and AhR 
protein levels, suggesting that the RNA editing-dependent down-regulation of AhR by miR-
378 contributes to the variability in the constitutive hepatic expression of AhR. This is the 
first evidence to reveal that A-to-I RNA editing modulates the potency of xenobiotic 
metabolism in the human liver. 
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7. RNA editing of human DHFR, which modulates PD  
RNA editing can occur in the transcripts of a drug target, possibly affecting the drug 
response (Streit & Decher, 2011; Decher et al., 2013). We recently found a clinical 
significance to the RNA editing of dihydrofolate reductase (DHFR) expression. 
DHFR is a key enzyme of folate metabolism. It catalyzes the reduction of dihydrofolate 
to form tetrahydrofolate using NADPH as a cofactor. Tetrahydrofolate is essential for the de 
novo synthesis of purine and thymidylate, which are required for DNA synthesis, cell growth 
and proliferation. Therefore, DHFR is a target of the chemotherapeutic agents methotrexate 
and pemetrexed (Schweitzer et al., 1990; Fowler. 2001; Nazki et al., 2014). The efficacy of 
methotrexate in cancer cells is often limited by the acquisition of resistance. As one of the 
mechanisms of methotrexate resistance, the overexpression of DHFR protein is recognized. In 
addition to the known mechanism, we recently found that DHFR expression in breast cancer 
is positively regulated by RNA editing via DHFR mRNA stabilization. For the underlying 
mechanism of the positive regulation of DHFR, we found that RNA editing destroys the 
binding sites of miR-25-3p and miR-125a-3p in the 3’-UTR of DHFR. (Nakano et al., 2017) 
(Fig. 4). The up-regulation of DHFR enhanced cellular proliferation and resistance to 
methotrexate. The editing levels in breast cancer tissues were higher than in normal tissues, 
suggesting a possibility that hyper-editing of the DHFR transcript could be responsible for 
increased DHFR expression. ADAR1 may be a potential anti-tumor target for anti-folate 
compounds, including methotrexate. 
 
8. Potential effects of editing in miRNA on PK and PD 
We and other research groups have revealed the impacts of miRNA-mediated regulation 
on drug metabolism-related genes (Nakajima & Yokoi 2011; Li et al., 2016). For CYP 
enzymes, human CYP1A1 (Choi et al., 2012), CYP1B1 (Tsuchiya et al., 2006), CYP2A6 
(Nakano et al., 2015a), CYP2B6 (Jin et al., 2016), CYP2C8 (Zhang et al., 2012), CYP2C9 
(Riger et al., 2015; Yu et al., 2015a), CYP2C19 (Zhang et al., 2012; Yu et al., 2015b), 
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CYP2E1 (Mohri et al., 2010; Nakano et al., 2015b; Miao et al., 2016) and CYP3A4 (Pan et 
al., 2009; Wei et al., 2014; Shi et al., 2015) have been revealed to be regulated by miRNAs. 
Such accumulating evidence indicates that miRNA is an important determinant of drug 
efficacy and toxicity. However, it remains to be clarified how the expression of miRNAs that 
regulate PK/PD-related genes is regulated. As mentioned above, the RNA editing in miRNA 
molecules has the potential to change their expression and function. In Table 3, miRNAs that 
regulate PK-related genes and have RNA editing sites in their pre-miRNA are summarized. To 
further elucidate the impact of RNA editing on PK/PD, the effects of the RNA editing of pre-




At present, the critical roles of RNA editing in physiological processes and their 
involvement in human diseases are becoming clear. The significance of RNA editing in the 
research field of PK/PD has only recently started to become clear, and this post-
transcriptional modulation could be an additional solid factor that causes intra- and inter-
individual differences in drug response. The issues that would make it possible for RNA 
editing to become a part of pharmacotherapy are as follows: (1) The impact of RNA editing 
on the expression or function of PK-related genes should be examined, as the functional 
significance of RNA editing of the mRNAs shown in Table 2 is unknown. (2) It should be 
investigated whether the change of RNA editing levels could affect PK/PD properties in vivo. 
(3) It should be determined to what extent ADARs expression and RNA editing levels change 
under physiological conditions (aging, hormones, diet, alcohol, smoking, environmental 
chemicals, stress, and drugs). (4) Trials to examine whether ADARs can be a therapeutic 
target should be conducted. The development of molecules to modulate ADAR expression or 
activity may be challenging. Studies to uncover the roles of RNA editing of the genes 
associated with pharmacotherapy would also provide useful information for personalized 
medicine. 
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Table 1. RNA editing-associated diseases 
Disease ADAR involved Target Reference 
Amyotrophic lateral sclerosis (ALS) ADAR2 GluR2 Kawahara et al., 2004 
   Kwak & Kawahara, 2005 
   Hideyama et al., 2010 
    
Hepatocellular carcinoma ADAR1 AZIN1 Chan et al., 2014 
 ADAR2 miR-214 Liu et al., 2013 
    
Melanoma ADAR1 miR-455-5p Shosan et al., 2015 
    
Glioblastoma ADAR2 CDC14B Galeano et al., 2013 
 ADAR2 miR-376* Choudhury et al., 2012 
 ADAR2 miR-21/221/222 Tomaselli et al., 2015 
 ADAR2 GluR2 Ishiuchi et al., 2002 
    
Prostate cancer ADAR1 PRUNE2/PCA3 Sarameh et al., 2015 
    
Type 2 diabetes mellitus  ADAR2 Unknown Gan et al., 2006 
   Yang et al., 2010 
    
Prader-Willi syndrome (PWS) ADAR1/ADAR2 5-HT2C-R Morabito et al., 2010 
    
Dyschromatosis symmetrica 
hereditaria (DSH) 
ADAR1 Unknown Miyamura et al., 2003 
   Tojo et al., 2006 
   Liu et al., 2006 
    
Aicadi-Goutières syndrome (AGS) ADAR2 Unknown Rice et al., 2007 
    
Alzheimer's disease ADAR2 GluR2 
Gaisler-Salomon et al., 
2014 
    
HIV-1 infection ADAR1 Viral p24 Gag Doria et al., 2009 
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Table 2. Drug metabolizing enzymes, transporters, and transcriptional factors that are subjected to RNA editing    
Drug metabolizing  
enzyme 




ADH1B Intron, 3'-UTR  BCRP (ABCG2) Intron  AhR 3'-UTR 
ADH1C Coding region  MRP2 (ABCC2) Intron  CAR (NR1I3) Intron 
AKR1C1 Intron, 3'-UTR  OAT2 (SLC22A2) Intron  FXR (NR1H4) Intron 
AKR1C2 Intron  OAT3 (SLC22A8) Coding region  GR (NR3C1) Intron 
CES2 3'-UTR  OATP1A2 (SLCO1A2) Intron  LXR (NR1H3) Intron 
COMT Intron  OATP1B1 (SLCO1B1) Intron  PXR (NR1I2) Intron 
CYP1A2 Intron, 3'-UTR  OATP2B1 (SLCO2B1) Intron  VDR Intron, 3'-UTR 
CYP1B1 Intron  OCT1 (SLC22A1) Intron    
CYP2B6 Intron, 3'-UTR  OCTN2 (SLC22A5) Intron    
CYP2C8 5'-UTR, intron  PEPT1 (SLC15A1) Intron, 3'-UTR    
CYP2C9 Intron  P-gp (ABCB1) Intron    
CYP2C18 Intron  URAT1 (SLC22A12) Intron    
CYP2D6 Intron       
CYP2E1 Intron       
CYP3A4 Intron       
CYP3A7 Intron       
FMO1 Intron       
FMO2 Intron       
FMO3 Intron       
FMO4 Intron       
FMO5 5'-UTR, coding region, intron       
SULT1A1 Intron, 3'-UTR       
TPMT Intron, 3'-UTR       
UGT2B15 Intron             
From RADAR (http://rnaedit.com/search/)     
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Target gene Reference 
miR-7 Pre-miR-7-2 +41 P-gp (ABCB1) Liu et al., 2015 
miR-27a Pre-miR-27a +17, +24 CYP3A4 Shi et al., 2015 
   P-gp (ABCB1) 
Zhu et al., 2008 & 
Li et al.,2010 
   PPAR 
Lin et al., 2009 & 
Kim et al., 2010 
miR-27b Pre-miR-27b +13 CYP1B1 Tsuchiya et al., 2006 
   CYP3A4 Pan et al., 2009 
   PPAR Kida et al., 2011 
   PPAR 
Karbiener et al., 2009 & 
Jennewein et al., 2010 
   VDR Pan et al., 2009 
miR-222 Pre-miR-222 +10 ER Zhao et al., 2008 
miR-223 Pre-miR-223 +91 P-gp (ABCB1) Yang et al., 2013 
miR-379 Pre-miR-379 +10 MRP2 (ABCC2) 
Haenisch et al., 2011 & 
Werk et al., 2014 
miR-508 Pre-miR-508 +31 P-gp (ABCB1) Shang et al., 2014 
miR-532 Pre-miR-532 +34 CYP3A4 Wei et al., 2014 
miR-641 Pre-miR-641 +24, +30, +31 CYP3A4 Yan et al., 2017 
miR-376c Pre-miR-376c +48, +50 UGT2B15 
Margaillan et al., 2015 & 
Wijayakumara et al., 2015 
      UGT2B17 
Margaillan et al., 2015 &  
Wijayakumara et al., 2015 
These pre-miRNAs are registered in RADAR (http://rnaedit.com/search/). 
aThe numbering denotes the 5' end of the pre-miRNA as +1. 
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Figure Legends 
 
Fig. 1. A-to-I RNA editing, which refers to the deamination of adenosine to inosine in the 
RNA molecule. Adenosine deaminase acting on RNA (ADAR) enzymes convert adenosine to 
inosine by hydrolytic deamination. Inosine is recognized by the cellular machinery as if it 
were guanosine.  
 
Fig. 2. Functional significance of A-to-I RNA editing. A-to-I editing occurs in double-
stranded RNA structure. Editing in the coding region of pre-mRNA may change the amino 
acid sequence. Editing in the intron may affect splicing by generating or deleting alternative 
splice sites. The editing events within the 3’-untranslated region (3’-UTR) have the potential 
to create or destroy the binding site of miRNAs. The A-to-I change in a miRNA transcript can 
alter its processing, thereby affecting miRNA expression. A-to-I editing of the miRNA seed 
sequence could change its target selection or binding efficiency. 
 
Fig. 3. The down-regulation of aryl hydrocarbon receptor (AhR) expression by RNA editing. 
The 3’-UTR of AhR is edited by ADAR1, and the edited sequence of AhR is recognized by 
miR-378 in human liver cells. This mechanism affects the expression and induction of drug-
metabolizing enzymes that are downstream of AhR.  
 
Fig. 4. The up-regulation of dihydrofolate reductase (DHFR) expression by RNA editing. The 
3’-UTR of DHFR is edited by ADAR1, and the edited DHFR mRNA can escape from 
repression by miR-25-3p and miR-125a-3p, leading to an increase in DHFR expression in 
breast cancer cells with high ADAR1 expression. This mechanism affects cellular 
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